As of December 31, 2023, there were 2,192,067 shares available under the 2017 Plan including shares that were forfeited under the prior plans for future issuance.

One-third of the total number of shares subject to each stock option vest ratably on each of the first three anniversaries of the grant date, contingent on continued employment, and subject to accelerated vesting in certain circumstances. There were no NQOs granted during the six months ended December 31, 2023.


Outstanding NQOs:	Number of NQOs	Weighted Average Exercise Price ($)	Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value ($ in thousands)
Outstanding at June 30, 2023	331,658	11.69	3.35	$	—
Granted	—	—	—	—
Exercised	—	—	—	—
Cancelled/Forfeited	—	—	—	—
Expired	(312,208)	11.31	—	—
Outstanding at December 31, 2023	19,450	17.75	2.64	$	—
Exercisable at December 31, 2023	19,450	17.75	2.64	$	—

At December 31, 2023 and June 30, 2023, there was no unrecognized NQO compensation cost. Total compensation expense for NQOs was $24 thousand and $0.1 million for the three and six months ended December 31, 2022.


Outstanding PNQs:	Number of PNQs	Weighted Average Exercise Price ($)	Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value ($ in thousands)
Outstanding at June 30, 2023	991	32.85	0.36	$	—
Granted	—	—	—	—
Exercised	—	—	—	—
Cancelled/Forfeited	—	—	—	—
Expired	(991)	32.85	—	—
Outstanding at December 31, 2023	—	—	0.00	$	—
Exercisable at December 31, 2023	—	—	0.00	$	—


Outstanding and Nonvested Restricted Stock Awards:	Shares Awarded	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2023	882,554	6.14
Granted	292,651	2.50
Vested/Released	(226,993)	6.66
Cancelled/Forfeited	(306,086)	6.61
Outstanding and nonvested at December 31, 2023	642,126	4.05

The weighted average grant date fair value of RSUs granted during the quarter ended December 31, 2023 and 2022 were $2.42 and $6.15, respectively. The total grant-date fair value of restricted stock granted during the six months ended December 31, 2023 was $0.7 million. The total fair value of awards vested during the six months ended December 31, 2023 and 2022 were $0.6 million and $1.6 million, respectively.

At December 31, 2023 and June 30, 2023, there was $1.5 million and $3.6 million, respectively, of unrecognized compensation cost related to restricted stock. The unrecognized compensation cost related to restricted stock at December 31, 2023 is expected to be recognized over the weighted average period of 2.1 years. Total compensation expense for restricted stock was $0.4 million and $0.7 million, respectively, in the three months ended December 31, 2023 and 2022. Total compensation expense for restricted stock was $1.0 million and $1.4 million, respectively, in the six months ended December 31, 2023 and 2022.


Outstanding and Nonvested PBRSUs:	PBRSUs Awarded (1)	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2023	549,291	5.92
Granted	180,000	2.42
Vested/Released	(134,660)	4.10
Cancelled/Forfeited	(414,631)	6.51
Outstanding and nonvested at December 31, 2023	180,000	2.42

The weighted average grant date fair value of PBRSUs granted during the quarter ended December 31, 2023 and 2022 were $2.42 and $6.40, respectively. The total grant-date fair value of PBRSU granted during the six months ended December 31, 2023 was $0.4 million. The total fair value of awards vested during the six months ended December 31, 2023 and 2022 were $0.3 million and $3 thousand, respectively.

At December 31, 2023 and June 30, 2023, there was $0.4 million and $1.7 million, respectively, of unrecognized PBRSU compensation cost. The unrecognized PBRSU compensation cost at December 31, 2023 is expected to be recognized over the weighted average period of 2.9 years. Total compensation expense for PBRSUs was $22 thousand and $0.2 million, respectively, for the three months ended December 31, 2023 and 2022. Total compensation expense for PBRSUs was $0.2 million and $0.4 million, respectively, for the six months ended December 31, 2023 and 2022.

CSRSUs vest in equal installments over a three-year period from the grant date, and are cash-settled upon vesting based on the closing share price of Common Stock on the vesting date.

The CSRSUs are accounted for as liability awards, and compensation expense is measured at fair value on the date of grant and recognized on a straight-line basis over the vesting period net of forfeitures. Compensation expense is remeasured at each reporting date with a cumulative adjustment to compensation cost during the period based on changes in the closing share price of Common Stock.


Outstanding and Nonvested CSRSUs:	CSRSUs Awarded	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2023	184,807	6.15
Granted	556,000	2.42
Vested/Released	(63,934)	6.25
Cancelled/Forfeited	(27,380)	6.46
Outstanding and nonvested at December 31, 2023	649,493	2.92

The weighted average grant date fair value of CRSUs granted during the quarter ended December 31, 2023 and 2022 were $2.42 and $6.40, respectively. The total grant-date fair value of CRSU granted during the six months ended December 31, 2023 was $1.3 million. The total fair value of awards vested during the six months ended December 31, 2023 and 2022 was $0.2 million and $0.2 million, respectively.

At December 31, 2023 and June 30, 2023, there was $1.7 million and $0.4 million, respectively, of unrecognized compensation cost related to CSRSU. The unrecognized compensation cost related to CSRSU at December 31, 2023 is expected to be recognized over the weighted average period of 2.7 years. Total compensation expense for CSRSUs was $0.1 million and $0.1 million, respectively for the three months ended December 31, 2023 and 2022. Total compensation expense for CSRSUs was $0.2 million and $0.1 million, respectively for the six months ended December 31, 2023 and 2022.